A multicentre trial to evaluate the use of serial carcinoembryonic antigen (CEA) assay as the prime indicator for second-look surgery in recurrent colorectal cancer

Submission date	Recruitment status	Prospectively registered
01/07/2001 Registration date	No longer recruiting Overall study status	☐ Protocol
		Statistical analysis plan
01/07/2001	Completed Condition category	[X] Results
Last Edited		Individual participant data
16/05/2014	Cancer	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Colon, rectum

Interventions

All patients receive primary potentially curative surgery. Patients are randomised if a significant rise in serum CEA is detected to either:

- 1. Conventional Arm: Observation only. The patient is monitored until there is clinical evidence of recurrent disease. The clinician is not informed of the rise in serum CEA.
- 2. Aggressive Arm: The surgeon is informed of the rise in serum CEA, and in the absence of objective evidence either of a non-malignant cause for the CEA rise or of incurable distant metastases, second-look laparotomy is carried out to locate and remove treatable recurrence.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1998

Completion date

31/12/2000

Eligibility

Key inclusion criteria

- 1. Aged 75 or under
- 2. Potentially curative resection performed for colorectal adenocarcinoma
- 3. No evidence of distant incurable spread (clinically or at surgery)
- 4. No evidence of hepatic, renal, pancreatic or infective disease
- 5. Willing to attend regular CEA monitoring in addition to clinical follow-up for 5 years

Participant type(s)

Patient

Age group

Adult

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1998

Date of final enrolment

31/12/2000

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123 Lincoln's Inn Fields London United Kingdom WC2A 3PX +44 (0)207 317 5186 kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	13/05/2014		Yes	No